Author Archives: Warren Woessner

New Edition of C.I.P.A. Guide to Patent Acts Published

This “Guide” is a 1528 page book published by the Chartered Institute of Patent Attorneys via Thomson Reuters, and edited by Paul Cole and Richard Davis. Of course, it mostly focused on UK patent law, but draws upon a variety … Continue reading

Posted in Non-U.S. Practice | Tagged , , | Leave a comment

Solicitor General’s Vanda Brief Deconstructs Mayo

When I was writing my post on INO Therapeutic’s Petition for Cert. on March 16th, I noticed the cite to the “invitation brief in Hikma Pharmaceuticals USA, Inc. v. Vanda Pharmaceuticals Inc., No. 18-817 (U.S. Dec. 6, 2019)(“the brief”). While … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , | Leave a comment

Illumina v. Ariosa – The “Bucket” to Be In

Today, a divided Fed. Cir. panel reversed the district court’s decision invalidating the claim of two Illumina patents, U.S. Pat. Nos. 9,580,751 and 9,738,931, as directed to a natural phenomenon (Illumina, Inc. v. Ariosa Diagnostics, Inc., Appeal No. 2019-1419 (Fed. … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , | Leave a comment

INO v. Praxair – Time for the Supreme Court to Step Up to the Plate?

Before you read this post, please back up and read my post of September 3, 2019 which discusses the Fed. Cir.’s ruling that the claims of U.S. Pat. No. 8,794,742 are patent-ineligible as attempts to claim a natural phenomenon. The … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , | Leave a comment